ClinicalTrials.gg
Sign In
CompletedNCT04351542Updated Apr 17, 2020

Ayurveda for Flu Like Illness During Covid-19 Outbreak

An interventional study of Ayurveda and Usual Care in Flu Like Illness, sponsored by Aarogyam UK. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-04-17.

Sponsored by Aarogyam UK · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study aimed to evaluate the efficacy and safety of Ayurveda in reducing symptoms of flu like illness during the Covid 19 outbreak.

02

Conditions studied

  • Flu Like Illness
03

In context

Lead sponsor

Aarogyam UK is the lead sponsor of 20 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with fu like symptoms within 48 hours of onset during March2020
  • Mild to moderate symptoms who were advised to self isolate at home for 7-14 days
  • Flu like symptoms present at least one respiratory symptom (e.g. cough, nasal obstruction, sore throat) and at least one constitutional symptom other than fever (e.g. fatigue, headache, myalgias) of less than 48-hour duration
  • Willing to consent and follow up

Exclusion criteria

Exclusion Criteria:

  • Pregnant/lactating

    • Participants with chronic pulmonary diseases or critical condition or already developed severe respiratory distress
    • Clinically malignancies, systemic infection, other medical or psychiatric condition which places the subject at unacceptable risk to participate in the study - Known hypersensitivity to any ayurveda herbal substances
  • Severe symptoms of respiratory distress patients deemed to require intensive care immediately
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Ayurveda Care Group

    Individualised ayurveda treatment was given to participants based on individual constitution.

    Dietary Supplement: Ayurveda · Other: Usual Care

  • Active comparator
    Usual Care Group

    Participants followed the usual care.

    Other: Usual Care

Interventions

  • Dietary supplementAyurveda

    Based on individual constitution (ayurveda based assessment) and symptoms an individual has, ayurveda herbal supplement and self managed practices were advised along with usual care recommendation.

  • OtherUsual Care

    Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.

06

What researchers measure

Primary outcomes

  1. Time to achieve afebrile

    Time to bring down a fever (oral temperature \< 37.2 ̊C)

    Time frame: Change from baseline to 3rd and 7th-day

  2. Severity of symptom score

    Symptoms diary card completed twice daily from Day 0 to Day 7

    Time frame: Change from baseline to 3rd and 7th day

Secondary outcomes

  1. Patient reported improvement

    Patient reported improvement using 4 scale; 0-none, 1-weak, 2-medium, 3-strong

    Time frame: Change from baseline to 3rd and 7th-day

07

Study locations

1 site
  • Aarogyam
    Leicester, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Apr 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2020
First posted
Apr 17, 2020
StartActual
Mar 6, 2020
Primary completionActual
Apr 6, 2020
CompletionActual
Apr 12, 2020
Last update
Apr 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04351542
Lead sponsor
Aarogyam UK
Responsible party
Sponsor
First posted
Apr 17, 2020
Start date
Mar 6, 2020
Primary completion
Apr 6, 2020
Completion
Apr 12, 2020
Last update
Apr 17, 2020

Study contacts

Neha Sharma, PhD
principal investigator · Aarogyam UK
Jaydeep Joshi, BAMS
study director · Aarogyam UK

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Aarogyam UK

Start the discussion